| Trial ID # | NCT01462890; AGO-OVAR17 |
| Phase | III |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Bevacizumab, Carboplatin, Paclitaxel |
| Eligible Participant | Newly diagnosed stage IIb-IV ovarian cancer |
| Patients Enrolled | 927 |
| Therapy Setting | First-line |
| Study Design | Open-Label, Randomized |
| Endpoints | PFS, OS, evaluated per RECIST |
| Efficacy | CarboPt+Pac+Bev (15 months, n=464) vs CarboPt+Pac+Bev (30 months, n=463): PFS: 24.2 vs 26.0 months, HR: 0.99 (0.85-1.15, p=0.90) |
| Clinically Significant Adverse Events | Serious AE: overall (11 vs 14%) |
| Conclusion | Longer treatment with bevacizumab for up to 30 months improves neither PFS nor OS in patients with newly diagnosed ovarian cancer. Therefore bevacizumab treatment duration of 15 months remains standard of care |
| Reference | Pfisterer J et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol (2023) 41(4):893-902 |